Alternatively, UHRF1 targeting may allow for the rational choice of either type of drugs in the course of RB treatment as the identified mechanisms underlying the potential therapeutic effects of UHRF1 depletion such as defects in DNA repair and intracellular ROS detoxification may affect the efficacy of both types of drugs. Here, UHRF1 is linked to retinoblastoma.